{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:25:13Z","timestamp":1785306313539,"version":"3.55.0"},"reference-count":41,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Roche Austria GmbH"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["DIGITAL HEALTH"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting 2.9 million people worldwide, often leading to permanent disability. MS patients frequently use eHealth tools due to their relatively young age. The Floodlight\n                      <jats:sup>\u00ae<\/jats:sup>\n                      MS app is a scientifically designed smartphone application that helps patients monitor hand motor skills, walking ability and cognition between medical appointments. This study assesses the cost-effectiveness of using the Floodlight\n                      <jats:sup>\u00ae<\/jats:sup>\n                      MS app alongside standard-of-care (SoC) versus SoC alone in patients with relapsing-remitting MS (RRMS) from the perspective of the healthcare system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A 10-year decision-analytic model was developed to assess the cost-effectiveness of incorporating the Floodlight\n                      <jats:sup>\u00ae<\/jats:sup>\n                      MS app alongside SoC. The analysis included treatment-naive individuals and those already on drug therapy, modelling the app's role in early detection of disease progression and relapses to improve quality-of-life.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For treatment-naive patients, using the Floodlight\n                      <jats:sup>\u00ae<\/jats:sup>\n                      MS app resulted in a 2,660 \u20ac increase in total costs but yielded potential medical-cost savings of 786 \u20ac through health improvements. These patients experienced fewer relapses and slower disability progression, translating to a quality-of-life improvement of 4.5 months in perfect health and an incremental-cost-effectiveness-ratio (ICER) of 7,071 \u20ac. Pre-treated patients showed similar trends, with medical-cost savings of 718 \u20ac, an ICER of 7,864 \u20ac, and a quality-of-life improvement of 4.2 months. Higher effectiveness (+5%) led to an additional 8.3 months in perfect health and a reduction in overall costs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The analysis demonstrates that the Floodlight\n                      <jats:sup>\u00ae<\/jats:sup>\n                      MS app is a cost-effective digital health application, encouraging broader discussions on maximizing the potential of software-as-medical-devices within the care pathway.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552076251314550","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T07:44:03Z","timestamp":1738655043000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of the Floodlight\n                    <sup>\u00ae<\/sup>\n                    MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1533-8912","authenticated-orcid":false,"given":"Evelyn","family":"Walter","sequence":"first","affiliation":[{"name":"IPF Institute for Pharmaeconomic Research, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matth\u00e4us","family":"Traunfellner","sequence":"additional","affiliation":[{"name":"IPF Institute for Pharmaeconomic Research, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Meyer","sequence":"additional","affiliation":[{"name":"IPF Institute for Pharmaeconomic Research, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Enzinger","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Graz, Graz, \rAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Guger","sequence":"additional","affiliation":[{"name":"Department of Neurology, Pyhrn-Eisenwurzen Hospital Steyr, Steyr, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bsteh","sequence":"additional","affiliation":[{"name":"Neurology and Psychiatry, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-3693","authenticated-orcid":false,"given":"Patrick","family":"Altmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hegen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Goger","sequence":"additional","affiliation":[{"name":"Innovation Hub Lead, Roche Austria GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Mikl","sequence":"additional","affiliation":[{"name":"Innovation Hub Lead, Roche Austria GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"bibr1-20552076251314550","unstructured":"Multiple Sclerosis International Federation (MSIF) \u201cAtlas of MS.\u201d Multiple Sclerosis International Federation. https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms; Assessed 06.11.2023. 2023."},{"key":"bibr2-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70242-9"},{"key":"bibr3-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1159\/000479696"},{"key":"bibr4-20552076251314550","unstructured":"Baumhackl U, Berger T, Enzinger C. \u00d6MSB \u00d6sterreichische Multiple Sklerose Bibliothek Evidenzbasierte Informationen zu allen Aspekten der MS f\u00fcr Betroffe-ne sowie \u00c4rzte und \u00c4rztinnen und Angeh\u00f6rige medizinischer Gesundheitsberufe. Wien, 2020."},{"key":"bibr5-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238658"},{"key":"bibr6-20552076251314550","volume":"21","author":"Midaglia L","year":"2019","journal-title":"J Med Internet Res"},{"key":"bibr7-20552076251314550","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Multiple Sklerose F\u00fchrt die Nutzung von mhealth-L\u00f6sungen (z. B. Apps) im Selbstmanagement der Betroffenen zu besseren Ergebnissen? IQWiG-Berichte \u2013 Nr. 1360, 2021."},{"key":"bibr8-20552076251314550","volume":"24","author":"Bevens W","year":"2022","journal-title":"Syst Rev Meta-Anal J Med Internet Res"},{"key":"bibr9-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.02.001"},{"key":"bibr10-20552076251314550","first-page":"640749","volume":"2010","author":"Lejbkowicz I","year":"2010","journal-title":"Mult Scler Int"},{"key":"bibr11-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.09.036"},{"key":"bibr12-20552076251314550","unstructured":"GKV Spitzenverband. Bericht des GKV-Spitzenverbandes \u00fcber die Inanspruch-nahme und Entwicklung der Versorgung mit digitalen Gesundheitsanwendungen (DiGA-Bericht). Berlin 2022. Online: https:\/\/www.gkv-spitzenver-band.de\/media\/dokumente\/krankenversicherung_1\/telematik\/digitales\/2022_DiGA_Bericht_BMG.pdf (Assessed 07.07.2023)."},{"key":"bibr13-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211028561"},{"key":"bibr14-20552076251314550","unstructured":"Regulation (EU) 2017\/745 of the European Parliament and of the Council on medical devices, Article 5(1)."},{"key":"bibr15-20552076251314550","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11091247"},{"key":"bibr16-20552076251314550","doi-asserted-by":"publisher","DOI":"10.2196\/46521"},{"key":"bibr17-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51705"},{"key":"bibr18-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1109\/JBHI.2023.3272117"},{"key":"bibr19-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11494-0"},{"key":"bibr20-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00790-2"},{"key":"bibr21-20552076251314550","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41598-023-50853-3","volume":"14","author":"Oh J","year":"2024","journal-title":"Sci Rep"},{"key":"bibr22-20552076251314550","unstructured":"F. Hoffmann-La Roche Ltd. Roche receives MDR certification for its science-based smartphone app Floodlight\u2122 MS, URL: https:\/\/diagnostics.roche.com\/global\/en\/news-listing\/2022\/roche-receives-mdr-certification-for-its-science-based-smartphone-app-floodlight-ms.html, Assessed: 17.11.2023."},{"key":"bibr23-20552076251314550","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11101305"},{"key":"bibr24-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1556668"},{"key":"bibr25-20552076251314550","unstructured":"Hemmer B, Bayas A, Berthele A, et al. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie, 2023, in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: www.dgn.org\/leitlinien (Assessed 15.10.2023)."},{"key":"bibr26-20552076251314550","volume":"20","author":"K\u00fchne F","year":"2022","journal-title":"Ger Med Sci"},{"key":"bibr27-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3041"},{"key":"bibr28-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"bibr29-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-006-0360-z"},{"key":"bibr30-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104951"},{"key":"bibr31-20552076251314550","volume":"7","author":"Kobelt G","year":"2006","journal-title":"Eur J Health Econ"},{"key":"bibr32-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-176X(199906)2:2<91::AID-MHP46>3.0.CO;2-I"},{"key":"bibr33-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418759189"},{"key":"bibr34-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517708099"},{"key":"bibr35-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2023.0106"},{"key":"bibr36-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1177\/1357633X16638971"},{"key":"bibr37-20552076251314550","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215013"},{"key":"bibr38-20552076251314550","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-7-18"},{"key":"bibr39-20552076251314550","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0016"},{"key":"bibr40-20552076251314550","doi-asserted-by":"publisher","DOI":"10.17925\/ENR.2013.08.S1.17"},{"key":"bibr41-20552076251314550","author":"Festanti A","journal-title":"The Importance of Quality Checks for Digital Health Studies Using Remote Unsupervised Assessments to Study Functional Impairment in MS"}],"container-title":["DIGITAL HEALTH"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552076251314550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552076251314550","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552076251314550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:51:01Z","timestamp":1777398661000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552076251314550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":41,"alternative-id":["10.1177\/20552076251314550"],"URL":"https:\/\/doi.org\/10.1177\/20552076251314550","relation":{},"ISSN":["2055-2076","2055-2076"],"issn-type":[{"value":"2055-2076","type":"print"},{"value":"2055-2076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"20552076251314550"}}